pharmaphorum

JUNE 24, 2025

Skip to main content Tuesday 24 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes 78

Diabetes Pharmaceutical Companies Pharmaceutical Companies Biosimilars 78

Pharmaceutical Technology

JULY 1, 2025

Reports Biosimilars in Immunology Data Insights The gold standard of business intelligence. Reports Biosimilars in Immunology Data Insights The gold standard of business intelligence. Go deeper with GlobalData Reports Chemotherapy in Pharmaceuticals: Platinum-based cancer drug composi. Find out more Sign up for our daily news round-up!

Packaging 52

Packaging Drug Development Chemotherapy Biosimilars 52

Pharmaceutical Technology

JULY 7, 2025

Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial (..)

Packaging 122

Packaging Communication Hospitals Drug Pricing 122

Pharmaceutical Technology

JULY 2, 2025

Kaftrio loses patient protection in 2037, at which point biosimilars are set to enter the market. Trikafta, known under the brand name Kaftrio in Europe, is the best-selling cystic fibrosis drug in the world, generating revenue of $11.02bn in 2024. Historically, this erodes the market dominance held by the branded drug.

Packaging 52

Packaging Communication Hospitals Drug Pricing 52

pharmaphorum

JULY 14, 2025

Skip to main content Monday 14 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes 52

Diabetes Pharmaceutical Companies Pharmaceutical Companies Biosimilars 52

pharmaphorum

JULY 1, 2025

Skip to main content Tuesday 1 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Vaccines 66

Vaccines Diabetes Pharmaceutical Companies Pharmaceutical Companies 66

Pharmaceutical Technology

JULY 4, 2025

Biosimilars and generics flood the market upon patent loss, which exerts pricing pressure on the branded product. There has been a push by the Trump administration to increase biosimilar and generic drug use in the US. Biosimilars and generics can be as much as 80% cheaper than branded alternatives.

Biosimilars 52

Biosimilars Chemotherapy Packaging Communication 52

Pharmaceutical Technology

JULY 7, 2025

Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial (..)

Hospitals 52

Hospitals Insurance Coverage and Processing Packaging Communication 52

Pharmaceutical Technology

JULY 7, 2025

Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial (..)

Packaging 52

Packaging Drug Development Drug Pricing Biosimilars 52

pharmaphorum

JUNE 6, 2025

Skip to main content Friday 6 June 2025 twitter linkedin facebook rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes 59

Diabetes Pharmaceutical Companies Pharmaceutical Companies Biosimilars 59

pharmaphorum

JUNE 17, 2025

Skip to main content Tuesday 17 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes 52

Diabetes Pharmaceutical Companies Pharmaceutical Companies Drug Pricing 52

Pharmaceutical Technology

JULY 10, 2025

Zentiva Group has entered into a licence and supply agreement with pharmaceutical company Lupin for the commercialisation of the latter’s biosimilar Certolizumab Pegol, a tumour necrosis factor alpha (TNFα) inhibitor medicine, across several markets. The partnership will enhance the availability of the affordable biosimilar on a global scale.

Biosimilars 52

Biosimilars Packaging Hospitals Communication 52

Pharmaceutical Technology

JUNE 24, 2025

Can pharma tariffs “Make America Manufacture Again”?

Packaging 52

Packaging Communication Hospitals Pharmaceutical Manufacturing 52

Pharmaceutical Technology

JULY 4, 2025

Biocon Biologics’ Denosumab biosimilars, Vevzuo and Evfraxy, have received marketing authorisation in the European Union (EU). Clinical trials have demonstrated that both biosimilars match the reference product’s safety, quality and efficacy standards.

Biosimilars 52

Biosimilars Chemotherapy Packaging Communication 52

Pharmaceutical Technology

JUNE 24, 2025

Can pharma tariffs “Make America Manufacture Again”?

Hospitals 52

Hospitals Packaging Communication Pharmaceutical Manufacturing 52

Pharmaceutical Technology

JUNE 24, 2025

Can pharma tariffs “Make America Manufacture Again”?

Compounding 52

Compounding Packaging Online Pharmacies Communication 52

Pharmaceutical Technology

JULY 7, 2025

Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial (..)

Packaging 52

Packaging Adverse Reactions Communication Hospitals 52

pharmaphorum

JUNE 30, 2025

Skip to main content Monday 30 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes 52

Diabetes Pharmaceutical Companies Pharmaceutical Companies Drug Development 52

Pharmaceutical Technology

JULY 11, 2025

Go deeper with GlobalData Reports LOA and PTSR Model - Bevacizumab Biosimilar in Endometrial Cancer Reports LOA and PTSR Model - Iparomlimab + Tuvonralimab in Nasopharyngeal C. NPC is a rare type of cancer in which malignant cells are formed in the upper part of the throat behind the nose. Find out more Sign up for our daily news round-up!

Packaging 52

Packaging Hospitals Biosimilars Communication 52

Pharmaceutical Technology

JULY 7, 2025

Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial (..)

Labelling 52

Labelling Packaging Communication Hospitals 52

Pharmaceutical Technology

JUNE 17, 2025

In February 2025, Teva and Alvotech have announced the US launch of the Selarsdi (ustekinumab-aekn) injection, a biosimilar to Johnson & Johnson’s Stelara (ustekinumab). This targeted method could significantly improve patient outcomes across multiple oncology diseases. Sign up for our daily news round-up!

Communication 52

Communication Hospitals Drug Development Packaging 52

pharmaphorum

JULY 1, 2025

Skip to main content Tuesday 1 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes 52

Diabetes Pharmaceutical Companies Pharmaceutical Companies Biosimilars 52

pharmaphorum

JULY 7, 2025

Skip to main content Monday 7 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Insurance Coverage and Processing 52

Insurance Coverage and Processing Diabetes Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

JUNE 27, 2025

Trump’s ‘most favoured nation’ model comes at a time when the administration has been vocal on its support for generics and biosimilars – copycat drugs that offer patients a cheaper entry point to treatment. It also goes some way to explaining the sheer volume of patients turning to compounded GLP-1RAs for weight loss.

Drug Pricing 59

Drug Pricing Compounding Packaging Communication 59

pharmaphorum

JULY 1, 2025

Skip to main content Tuesday 1 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes 52

Diabetes Pharmaceutical Companies Pharmaceutical Companies Biosimilars 52

pharmaphorum

JUNE 27, 2025

Skip to main content Friday 27 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes 52

Diabetes Pharmaceutical Companies Pharmaceutical Companies Biosimilars 52

pharmaphorum

JULY 2, 2025

Skip to main content Wednesday 2 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes 52

Diabetes Pharmaceutical Companies Pharmaceutical Companies Drug Development 52

Pharmaceutical Technology

JUNE 13, 2025

While the overall MG market is expected to experience growth until 2034, continued generic erosion and the entry of biosimilars will be important barriers to growth. Generic erosion and the entry of biosimilars are expected to be particularly significant in the US MG market. s Zilbrysq (zilucoplan). s Zilbrysq (zilucoplan).

Biosimilars 52

Biosimilars Communication Hospitals Vaccines 52

pharmaphorum

JUNE 26, 2025

Skip to main content Thursday 26 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes 83

Diabetes Pharmaceutical Companies Pharmaceutical Companies Biosimilars 83

pharmaphorum

JUNE 19, 2025

Skip to main content Thursday 19 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Vaccines 52

Vaccines Diabetes Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

JULY 22, 2025

Skip to main content Tuesday 22 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes 52

Diabetes Pharmaceutical Companies Pharmaceutical Companies Biosimilars 52

pharmaphorum

JULY 9, 2025

Skip to main content Wednesday 9 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes 52

Diabetes Pharmaceutical Companies Pharmaceutical Companies Biosimilars 52

pharmaphorum

JUNE 17, 2025

billion takeover bid for Verve Therapeutics, upgrading a collaboration between the two companies that dates back to 2023. billion takeover bid for Verve Therapeutics, upgrading a collaboration between the two companies that dates back to 2023.

Diabetes 59

Diabetes Pharmaceutical Companies Pharmaceutical Companies Biosimilars 59

pharmaphorum

JUNE 26, 2025

Skip to main content Thursday 26 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes 59

Diabetes Pharmaceutical Companies Pharmaceutical Companies Biosimilars 59

pharmaphorum

JULY 7, 2025

Skip to main content Monday 7 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes 100

Diabetes Pharmaceutical Companies Pharmaceutical Companies Labelling 100

Pharmaceutical Technology

JUNE 25, 2025

Go deeper with GlobalData Reports Biosimilars in Pharmaceuticals: Peptide-based compositions for Alzh. Over the past few decades, Alzheimer’s research and development (R&D) has seen a low success rate due to failure to demonstrate efficacy in clinical trials.

Packaging 59

Packaging Biosimilars Communication Hospitals 59

pharmaphorum

JUNE 23, 2025

Skip to main content Monday 23 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes 64

Diabetes Pharmaceutical Companies Pharmaceutical Companies Biosimilars 64